Regulatory Dendritic Cells Induced by Mesenchymal Stem Cells Ameliorate Dextran Sodium Sulfate-Induced Chronic Colitis in Mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Regulatory dendritic cells (rDCs), which can be induced by mesenchymal stem cells (MSCs), play an important role in inducing and maintaining homeostasis of regulatory T cells and exhibit anti-inflammatory functions. In this study, we investigated whether MSCs could differentiate DCs into rDCs and compared the therapeutic effects of rDCs and MSCs on dextran sodium sulfate (DSS)-induced chronic colitis mice. Methods: Immature DCs (imDCs) and lipopolysaccharide (LPS)-treated mature DCs (mDCs) were co-cultured with MSCs for 48 hours, and then the profiles of surface markers and cytokines and regulatory roles of these DCs for primary splenocytes were analyzed. In addition, the therapeutic effects of MSCs and DCs co-cultured with MSCs were compared in chronic colitis mice. Results: After co-culture of imDCs (MSC-DCs) or LPS-treated mDCs (LPS+MSCDCs) with MSCs, the expression of CD11c, CD80, CD86, interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), was decreased, but that of CD11b, IL- 10, and transforming growth factor-β (TGF-β) was increased. Furthermore, MSC-DCs and LPS+MSC-DCs induced the expression of CD4, CD25, and Foxp3 in primary splenocytes isolated from mice. In DSS-induced colitis mice, MSCs and MSC-DCs increased colon length, body weight, and survival rate and induced histological improvement. Moreover, in the colon tissues, the expression of IL-6, TNF-α, and IFN-γ decreased, but that of IL-10, TGF-β, and Foxp3 increased in the MSC- and MSC-DC-injected groups. Conclusions: Our data suggest that MSCs differentiate DCs into rDCs, which ameliorate chronic colitis. Thus, rDCs stimulated by MSCs may be therapeutically useful for the treatment of chronic inflammatory diseases.
Abstract
Background/Aims: Regulatory dendritic cells (rDCs), which can be induced by mesenchymal stem cells (MSCs), play an important role in inducing and maintaining homeostasis of regulatory T cells and exhibit anti-inflammatory functions. In this study, we investigated whether MSCs could differentiate DCs into rDCs and compared the therapeutic effects of rDCs and MSCs on dextran sodium sulfate (DSS)-induced chronic colitis mice. Methods: Immature DCs (imDCs) and lipopolysaccharide (LPS)-treated mature DCs (mDCs) were co-cultured with MSCs for 48 hours, and then the profiles of surface markers and cytokines and regulatory roles of these DCs for primary splenocytes were analyzed. In addition, the therapeutic effects of MSCs and DCs co-cultured with MSCs were compared in chronic colitis mice. Results: After co-culture of imDCs (MSC-DCs) or LPS-treated mDCs (LPS+MSCDCs) with MSCs, the expression of CD11c, CD80, CD86, interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), was decreased, but that of CD11b, IL- 10, and transforming growth factor-β (TGF-β) was increased. Furthermore, MSC-DCs and LPS+MSC-DCs induced the expression of CD4, CD25, and Foxp3 in primary splenocytes isolated from mice. In DSS-induced colitis mice, MSCs and MSC-DCs increased colon length, body weight, and survival rate and induced histological improvement. Moreover, in the colon tissues, the expression of IL-6, TNF-α, and IFN-γ decreased, but that of IL-10, TGF-β, and Foxp3 increased in the MSC- and MSC-DC-injected groups. Conclusions: Our data suggest that MSCs differentiate DCs into rDCs, which ameliorate chronic colitis. Thus, rDCs stimulated by MSCs may be therapeutically useful for the treatment of chronic inflammatory diseases.
참고문헌 (31)
- Zhang YZ, "Inflammatory bowel disease: pathogenesis", World J Gastroenterol, 20, pp.91~99 (2014)
- Bouma G, "The immunological and genetic basis of inflammatory bowel disease", Nat Rev Immunol, 3, pp.521~533 (2003)
- Klinker MW, "Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models", World J Stem Cells, 7, pp.556~567 (2015)
- Duijvestein M, "Stem cells as potential novel therapeutic strategy for inflammatory bowel disease", J Crohns Colitis, 2, pp.99~106 (2008)
- Dalal J, "Role of mesenchymal stem cell therapy in Crohn’s disease", Pediatr Res, 71(4 Pt 2), pp.445~451 (2012)
- Li W, "Mesenchymal stem cells: a doubleedged sword in regulating immune responses", Cell Death Differ, 19, pp.1505~1513 (2012)
- Figueroa FE, "Mesenchymal stem cell treatment for autoimmune diseases: a critical review", Biol Res, 45, pp.269~277 (2012)
- Djouad F, "Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals", Blood, 102, pp.3837~3844 (2003)
- Chen QQ, "Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses", World J Gastroenterol, 19, pp.4702~4717 (2013)
- Hyun Jung Lee, "Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis", Gut and Liver, 10(3), pp.412~419 (2016), 거트앤리버 소화기연관학회협의회
- Liu WH, "Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin- 10 and the JAK1", STAT3 signaling pathway, 2013, pp.8, e55487~
- Zhao ZG, "Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells", Immunol Invest, 41, pp.183~198 (2012)
- Zhang B, "Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population", Blood, 113, pp.46~57 (2009)
- Bernhard H, "Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood", Cancer Res, 55, pp.1099~1104 (1995)
- Banchereau J, "Immunobiology of dendritic cells", Annu Rev Immunol, 18, pp.767~811 (2000)
- Steinman RM, "Tolerogenic dendritic cells", Annu Rev Immunol, 21, pp.685~711 (2003)
- Mahnke K, "Immature, but not inactive: the tolerogenic function of immature dendritic cells", Immunol Cell Biol, 80, pp.477~483 (2002)
- Joffre O, "Inflammatory signals in dendritic cell activation and the induction of adaptive immunity", Immunol Rev, 227, pp.234~247 (2009)
- Bates J, "Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity", J Pathol, 232, pp.112~120 (2014)
- Chen L, "Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells", Stem Cells Dev, 16, pp.719~731 (2007)
- Spaggiari GM, "MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2", Blood, 113, pp.6576~6583 (2009)
- Sato K, "Regulatory dendritic cells protect mice from murine acute graft-versushost disease and leukemia relapse", Immunity, 18, pp.367~379 (2003)
- Wood KJ, "Regulatory immune cells in transplantation", Nat Rev Immunol, 12, pp.417~430 (2012)
- Rayudu V, "Effect of Triphala on dextran sulphate sodium- induced colitis in rats", Ayu, 35, pp.333~338 (2014)
- Zhu H, "A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone", Nat Protoc, 5, pp.550~560 (2010)
- Lin CS, "Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges", Histol Histopathol, 28, pp.1109~1116 (2013)
- Levings MK, "The role of IL- 10 and TGF-beta in the differentiation and effector function of T regulatory cells", Int Arch Allergy Immunol, 129, pp.263~276 (2002)
- Wallet MA, "Immunoregulation of dendritic cells", Clin Med Res, 3, pp.166~175 (2005)
- Sato K, "Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells", Blood, 101, pp.3581~3589 (2003)
- Chen W, "Tregs in immunotherapy: opportunities and challenges", Immunotherapy, 3, pp.911~914 (2011)
- Chen ZM, "IL-10 and TGFbeta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function", Blood, 101, pp.5076~5083 (2003)